scholarly journals A Nomogram From The SEER Database For Predicting The Prognosis of Small Cell Lung Cancer With Different Patterns of Metastases

2021 ◽  
Author(s):  
Hongli Ruan ◽  
Yanmei Liu ◽  
Huali Sun ◽  
Yan Ding ◽  
Shenpeng Ying ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liver Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastases ◽  
Small Cell ◽  
Seer Database ◽  
Small Cell Lung ◽  
Training Set ◽  
Validation Set

Abstract Backgroud: Distant metastases are one of the leading causes of high mortality in small cell lung cancer (SCLC). This research is aimed to investigate the different patterns of metastases in SCLC patients and their impact on prognosis based on the data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: The 2010-2015 SEER database of 15637 SCLC patients diagnosed from January to August were used as a training set for development of a nomogram. 7310 SCLC patients diagnosed from September to December were used as the validation set. Results: The overall survival (OS) of SCLC patients with no distant metastases, bone metastases, brain metastases, and liver metastases were 16.6, 9.1, 8.8 and 6.0 months, respectively. Patients with solitary liver metastases have the worst prognosis in the cases with single metastatic site. In the patients with multi-site metastases, the clinical outcomes of the cases combined with liver metastases were the worst. Our Cox model indicated that age, gender, American Joint Committee on Cancer (AJCC) stage, metastases, chemotherapy, radiation and surgery were independent predictors for OS in SCLC patients. The c-index value of nomogram was 7.52 in training set and 7.48 in of validation set for predicting OS in SCLC, indicating that the predictive ability of our nomogram model was of great superiority.Conclusion: The prognosis of SCLC patients with liver metastases alone or combined with other metastatic sites were worse than other metastatic models. Our nomogram model that integrated significant factors can aid as an individualized clinical predictive tool in SCLC patients.

scholarly journals Clinical features and outcome of small cell lung cancer in female patients: a large-cohort retrospective study

2020 ◽  
Author(s):  
Jia Hou ◽  
Yu Wang ◽  
Wenyuan Li ◽  
Xiao Wang ◽  
Jincan Hao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Clinical Characteristics ◽  
Distant Metastases ◽  
Small Cell ◽  
Seer Database ◽  
Small Cell Lung ◽  
Female Patients

Abstract Background: Currently, female small cell lung cancer (SCLC) incidence has been increasing. However, there have been few large database-based studies on female patients with SCLC. In this study, we used Surveillance, Epidemiology, and End Results (SEER) database to describe the clinical characteristics and prognosis of female SCLC patients.Methods: SCLC patients from the SEER database between 1973 and 2015 were included. Gender, age, race, stage, tumor size, and metastasis status were included in our study. Clinical characteristics were analyzed among females and males with SCLC. Survival analyses were conducted with log-rank tests and Cox proportional hazard models.Results: A total of 18234 patients were extracted from SEER database. 50.2% of the whole SCLC patients were females. Compared with males, females were less likely to be Asians, carry bigger size of tumor, have later TNM stage, and have distant metastases (P < 0.05). Gender proved to be an independent prognostic factor for SCLC patients (CSS:HR:1.105;95% CI: 1.068 1.143; P < 0.001; OS: HR, 1.120;95% CI: 1.084 1.158; P < 0.001). Female patients presented more favorable survival than male patients (Median OS/CSS:11 vs. 9 months, P < 0.001). Our results confirmed that age≥65, white race, later stage, tumor size ≥ 50mm and distant metastases were all associated with poor prognosis in female patients.Conclusions: Female gender is associated with more favorable outcome of SCLC. For females, patients who are senile, white people, and have poorer pathological features were associated with a shorter OS, which need to be more circumspectly treated in clinical practice.

scholarly journals Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer

2021 ◽  
Vol 10 (5) ◽  
pp. 1126
Author(s):  
Michał Szczyrek ◽  
Radosław Mlak ◽  
Aneta Szudy-Szczyrek ◽  
Karolina Kędziora ◽  
Teresa Małecka-Massalska ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Distant Metastases ◽  
Small Cell ◽  
Caspase 8 ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Platinum Based Chemotherapy

Caspase 8 is a protein involved in the process of cell apoptosis, which may affect the efficacy of anti-cancer treatment. The aim of our study was to determine the impact of polymorphisms in the CASP-8 gene encoding caspase 8 on the prognosis in non-small-cell lung cancer (NSCLC). The study involved 99 patients with newly diagnosed locally advanced or metastatic NSCLC treated with platinum-based chemotherapy. The presence of the GG genotype was associated with distant metastases, smoking, and a family history of cancer. The higher risk of early progression was associated with weight loss and the CASP-8 genotype (GG vs. AG or AA: 20.51% vs. 2.86%). The higher risk of progression-free survival (PFS) shortening was associated with a higher stage of disease (hazard ratio (HR) = 2.50, 95% CI: 1.61–3.89, p < 0.0001), distant metastases (HR = 2.30, 95% CI: 1.42–3.72, p = 0.0016), and the GG genotype (HR = 1.68, 95% CI: 1.10–2.57, p = 0.0152). The influence of the GG genotype on the PFS was confirmed in a multivariate analysis (HR = 1.80, 95% CI: 1.06–3.05, p = 0.0317). We did not confirm the influence of CASP-8 genotypes on the overall survival (OS).

Sign in / Sign up

Export Citation Format

Share Document